Artivion(AORT) Prnewswire·2025-02-24 21:05Core Insights - Artivion, Inc. reported strong financial performance for 2024, with total revenues reaching (13.4) million for the full year, an improvement from a net loss of 420 million and 97.3 million, a 4% increase on a GAAP basis compared to the same quarter in 2023 [5][14]. - The company reported a net loss of (4.0) million in Q4 2023 [6][14]. - Adjusted EBITDA for Q4 2024 increased by 15% to 15.3 million in Q4 2023 [14][27]. Product and Market Highlights - Revenue growth in Q4 was driven by a 10% increase in On-X mechanical heart valves and stent grafts, and an 8% increase in BioGlue compared to Q4 2023 [3][14]. - Latin America showed significant revenue strength, growing 26% in Q4 2024 on a constant currency basis compared to the previous year [3][14]. - The company received a Humanitarian Device Exemption from the FDA for the AMDS Hybrid Prosthesis, allowing it to deliver its technology to patients while pursuing PMA approval [4][14]. Operational Developments - Artivion submitted the second module of the PMA application to the FDA for the AMDS Hybrid Prosthesis [4][14]. - The company generated 11.0 million in non-GAAP free cash flow for the full year 2024 [14][26]. - The company is confident in its ability to drive sustained double-digit revenue growth and adjusted EBITDA growth at twice the pace of constant currency revenue growth in 2025 [4][10].